Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

    Thank You!

    Your message has been sent.

    Oops, message not sent.

    Please make sure fields are complete.

    News

    Chondrosarcoma Foundation Enters Fifth Year, Marks Progress


    The Chondrosarcoma (CS) Foundation will commemorate its fourth anniversary by continuing to educate the public about this rare bone cancer, advocate for patients fighting the disease and will report on a global natural history study. On May 14,…

    Read Article

    Rapamycin causes growth arrest and inhibition of invasion in human chondrosarcoma cells


    Rapamycin causes growth arrest and inhibition of invasion in human chondrosarcoma cells Jian Song1, Xiaobo Wang2, Jiaxue Zhu3, Jun Liu4 1Department of Orthopaedics, Shandong Jining No.1 People’s Hospital, Jining, Shandong, 272000, China;…

    Read Article

    Dan Hurley, M.D. Endowment Fund


    Daniel Brian Hurley, M.D. passed away August 3, 2023, from dedifferentiated chondrosarcoma at age 50 surrounded by his loved ones. His wife Traci and their three kids Rachel, Sam, and Sarah were the light of his life. His family, including his…

    Read Article

    Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes


    Ryan A Denu 1, Richard K Yang 2, Alexander J Lazar 2 3, Shalin S Patel 4, Valerae O Lewis 4, Jason Roszik 5, J Andrew Livingston 1, Wei-Lien Wang 2, Kenna R Shaw 6, Ravin Ratan 1, Maria A Zarzour 1, Justin Bird 4, Shaan Raza 7, Kadir C Akdemir 7,…

    Read Article

    Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes


    Ryan A Denu 1, Richard K Yang 2, Alexander J Lazar 2 3, Shalin S Patel 4, Valerae O Lewis 4, Jason Roszik 5, J Andrew Livingston 1, Wei-Lien Wang 2, Kenna R Shaw 6, Ravin Ratan 1, Maria A Zarzour 1, Justin Bird 4, Shaan Raza 7, Kadir C Akdemir 7,…

    Read Article

    Chondrosarcoma Foundation Efforts to Promote Genomic Sequencing Tests


    Genomic sequencing is a promising tool for expanding the treatment options for chondrosarcoma patients. Genomic sequencing technologies are capable of characterizing known and novel clinically relevant biomarkers, like IDH1/2, and is becoming a…

    Read Article

    Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options


    Abstract This review provides an overview of histopathology, clinical presentation, molecular pathways, and potential new systemic treatments of high-grade chondrosarcomas (CS), including grade 2–3 conventional, dedifferentiated, and mesenchymal…

    Read Article

    Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report


    Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report Veronika Blum, 1 , † Vanghelita Andrei, 2 , † Baptiste Ameline, 2 Silvia Hofer, 3 Bruno Fuchs, 1 Klaus Strobel, 1 Anna Allemann, 1 Beata Bode, 4…

    Read Article

    Contact Information


    If you would like to learn more about CS Foundation or if you would like to learn more about the resources we provide to patients, families, caregivers, and physicians, please contact us by phone or send us a message.

    **A Registered 501c3 Non-Profit Charity Organization. All donations are tax-deductible.**

    Send a Message